Skip to content

Cognitive

All peptides
Synthetic adamantane derivative (anti-asthenic / actoprotector)

Bromantane

Also known as: Ladasten, Bromantan, N-(2-adamantyl)-N-(p-bromophenyl)amine, ADK-709

Russian-developed anti-asthenic. Indirect dopaminergic effect via tyrosine hydroxylase upregulation. Tier 3 in Russian clinical literature; no Western replication. WADA-banned for athletes. Not technically a peptide — included for community completeness.

Reviewed 2026-05-11

What it does

Bromantane (commercialized as Ladasten in Russia) was developed at the Center of Drug Chemistry in the 1980s as an anti-asthenic — a class of drug targeting fatigue and exhaustion states. It is an adamantane derivative, structurally related to amantadine, and acts primarily as an indirect dopaminergic via upregulation of tyrosine hydroxylase (the rate-limiting enzyme in dopamine synthesis). It is registered in Russia for asthenia and asthenic-neurotic disorders; outside Russia it is unapproved and sold as a research compound. Bromantane gained brief Olympic notoriety in 1996 when several Russian athletes tested positive at the Atlanta Games, leading to its WADA listing — its actoprotective profile (preserves performance under physical / mental stress) is the source of the ban.

Used for

Dose

Starting
50,000 mcg · once daily
Common
75,000 mcg · once daily
Upper
100,000 mcg · once daily
When
MorningAnti-asthenic / actoprotector with mild stimulating effects. Morning dose pairs with the workday and avoids evening insomnia. Some users split dose AM + early afternoon if they find a single morning dose wears off.
Site
oral (tablet or capsule)

Need exact volumes? Open the peptide calculator →

⚠ Caution

  • Pregnancy and breastfeeding (no human safety data)
  • Active competitive athletics (WADA-banned substance; will produce a positive doping test for up to several weeks after last dose due to long urinary detection window)
  • Concurrent MAO inhibitors (theoretical risk via dopaminergic synergy; not characterized in clinical trials)
  • Known hypersensitivity to adamantane-class compounds (amantadine, memantine, rimantadine)
  • Acute psychosis or hypomania (theoretical risk via dopaminergic activity)

Your stack

Track this peptide in your protocol — dose, schedule, vials on hand, refill projection. Stays in your browser; no account needed.

Add to my stack

Use this peptide

Reconstitution & storage

Bromantane is supplied as an oral tablet (Ladasten 50mg in Russia) or as bulk powder for research use. No reconstitution required. Powder users should weigh carefully — 50-100 mg is a tiny visible amount and over-dosing is easy with a kitchen scale.

Storage. Room temperature, dry, protected from light. Stable as a solid for years.

Open the peptide calculator →

Monitoring & questions

Reported side effects
  • Generally well tolerated in Russian clinical trials at standard doses
  • Mild nausea, particularly when taken on an empty stomach
  • Headache (uncommon)
  • Paradoxical anxiety or restlessness in a subset of users — reported especially at higher community doses (>100 mg/day)
  • Insomnia if dosed late in the day
  • Long-term safety data outside the Russian clinical use context is essentially absent

Reference

How it works

Bromantane upregulates tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the striatum, increasing dopamine synthesis. It also has documented effects on serotonergic and GABAergic signaling, and modulates HPA-axis cortisol response under stress. The combined effect is anxiolytic-without-sedation plus mild cognitive enhancement plus improved tolerance for physical and mental fatigue — a distinct profile from classic stimulants (no dopamine reuptake inhibition, no direct receptor agonism). Effects are subtle and accumulate over days of dosing rather than acute.

EvidenceTier 3 — Animal / in vitro

Tiers are per indication. The same molecule can be Tier 1 for one use and Tier 4 for another — the tier reflects published literature, not community framing.

Asthenia (chronic fatigue, low motivation, exhaustion)

Tier 3medium confidence

Morozov 2009 — multi-center Russian RCT in 728 asthenia patients showed bromantane 50-100 mg/day for 28 days produced statistically significant improvements in fatigue, motivation, and cognitive endurance vs placebo. Reasonable sample size and methodology by Russian clinical-trial standards. Per Rule 5 of the evidence-tier-classifier skill (old, unreplicated, methodologically variable trials are weaker than they appear), capped at Tier 3 because no independent Western replication exists and the clinical literature is overwhelmingly Russian.

Morozov PV et al. 2009

Cognitive / nootropic effects in healthy adults

Tier 4low confidence

Animal studies and Russian human studies in clinical asthenia populations suggest pro-cognitive effects on attention and motivation. NO controlled trials in healthy adults — the nootropic-community use case for bromantane is extrapolation, not direct evidence. Tier 4 (anecdotal / theoretical) by the skill's classification.

Morozov PV et al. 2009

Anxiolysis with preserved cognitive function

Tier 3medium confidence

Russian work shows bromantane produces anxiety reduction without the sedation or cognitive blunting typical of benzodiazepines or first-generation antihistamines. Mechanistically plausible (mixed dopaminergic + GABAergic + serotonergic action) but not independently replicated outside Russia.

Morozov PV et al. 2009
Citations (1)
  1. [1]
    Efficacy and tolerability of Ladasten in the treatment of asthenia in patients with neurasthenia
    Morozov PV, Kost NV, Sokolov OY, et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2009 · PMID 19388366
    Primary Russian multi-center RCT (n=728) of bromantane in asthenia. Anchor citation for the Tier 3 asthenia indication.
    View source